ARWR Stock Price Today (April 2026) — Arrowhead Pharmaceuticals, Inc. Analysis & Key Metrics 2026-04-02
Arrowhead Pharmaceuticals, Inc. (ARWR) is trading at $65.35, up 3.86% today (as of April 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $81.09 (24.1% upside).
- Volatility remains elevated (49.00% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (104.61% YoY) alongside significant competitive pressures.
ARWR Stock Analysis: Key Metrics & Valuation (April 2026)
Concise, actionable data for investors
Arrowhead Pharmaceuticals, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $8.32B
P/E Ratio
Forward P/E: -14.20
Revenue Growth
Year over Year
Analyst Target
+24.1% upside potential
Key Investor Questions About ARWR
What investors need to know before buying
Based on current market data, ARWR presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 55.75)
- Fundamentals say: Caution warranted (high leverage concerns)
ARWR's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ARWR investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $698.16M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, ARWR stock traded between $9.57 and $76.76—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 49.00% annualized volatility and β=1.30, the stock exhibits high sensitivity to market moves—making ARWR suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Arrowhead Plozasiran Data Supports Triglyceride Reduction And Valuation Upside Potential
Arrowhead Pharmaceuticals released two year extension data for its RNAi therapy plozasiran in patients with severe and moderate hypertriglyceridemia. The study showed sustained triglyceride reduction alongside a favorable safety profile over the long term. Results were presented at a major cardiology conference and focus on patient groups at high risk of acute pancreatitis with limited treatment options. For investors tracking NasdaqGS:ARWR, the plozasiran update arrives after a mixed share...
SRPT Stock Surges on Promising Early Results From siRNA Programs
Sarepta Therapeutics shares surge 35% as early data from two siRNA therapies show strong target knockdown, safety and muscle delivery potential.
Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets
Johnson & Johnson’s restated fourth-quarter holdings report, filed last week, reveals that the company exited three biotechs while retaining its stakes in several rumored acquisition targets. The changes included the sale of 247,598 shares in Arrowhead Pharmaceuticals previously a partner of Johnson & Johnson’s Janssen unit, which rebranded as its Innovative Medicine division. Johnson & Johnson also exited BiomX another former collaborator, through the sale of 96,866 shares.
Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout?
Sarepta Therapeutics (NASDAQ:SRPT) stock is up approximately 20% in early trading on Wednesday after the company released its first-ever clinical data from two siRNA programs targeting rare neuromuscular diseases with no currently approved treatments. SRPT stock, which closed at $17.61 on Tuesday, is attracting fresh investor attention after years of turbulence tied to its gene ... Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout?
Sarepta sees early success with RNAi drugs from Arrowhead
Long-awaited results from Phase 1/2 studies lifted Sarepta’s stock and, according to the company, suggest potential for two medicines to treat muscle-weakening conditions.
Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies
SRPT plans FDA filings to convert Amondys 45 and Vyondys 53 to full approvals, leveraging new data despite a missed endpoint in its confirmatory study.
A Look At Arrowhead Pharmaceuticals (ARWR) Valuation As Recent Momentum Cools After A Strong Run
With no single headline event driving Arrowhead Pharmaceuticals (ARWR) today, recent trading and fundamentals still give you a few concrete markers to watch as you think about the stock. See our latest analysis for Arrowhead Pharmaceuticals. At a share price of US$56.96, Arrowhead’s 1-day and 7-day share price returns of 0.44% and 3.54% sit against a 30-day and 90-day share price pullback, while the 1-year total shareholder return is very large and well above the 3-year total shareholder...
Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of Billionaire Ken Fisher’s 15 Most Notable Moves for 2026. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a relatively recent addition to the 13F portfolio of Fisher Asset Management. The fund first disclosed a stake in the firm in filings for the second quarter of 2024, comprising close to 12,000 shares […]
SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study
Sarepta gains as enrollment begins in a new ENDEAVOR study cohort testing a sirolimus regimen to improve Elevidys safety in DMD patients.
Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is one of the best multibagger stocks to invest in according to billionaires. On February 5, Arrowhead Pharmaceuticals achieved a strategic turning point in FQ1 2026, transitioning into a commercial-stage organization following the US FDA approval of its first medicine, REDEMPLO (plozasiran). This siRNA therapeutic, designed to treat familial chylomicronemia syndrome/FCS, […]
Frequently Asked Questions
Common investor questions about Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) is currently trading at $65.35. The RSI (14-day) is at 55.7, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $81.09 implies 24.1% upside from current levels. Volatility is high at 49.0% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Arrowhead Pharmaceuticals, Inc. (ARWR): The trailing P/E ratio is 38.14, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is -14.20, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 14.75. Price-to-Sales is 7.83. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 11 analysts covering ARWR, the consensus price target is $81.09. This represents a 24.1% upside from the current price of $65.35. The range spans from a low target of $35.00 to a high target of $110.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Arrowhead Pharmaceuticals, Inc. (ARWR) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Arrowhead Pharmaceuticals, Inc. (ARWR) investors include: 1. High volatility (49.0% annualized)—the stock can experience significant daily price swings. 2. Elevated debt levels (D/E ratio of 124.07) which could pressure margins in a rising rate environment. 3. Elevated short interest (11.4% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Arrowhead Pharmaceuticals, Inc.'s (ARWR) current debt and financial health profile: Total debt stands at $698.16M. The debt-to-equity ratio is 124.07, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 3.38, indicating strong short-term liquidity. The quick ratio is 3.26. The company holds $914.71M in cash and equivalents. Free cash flow is positive at $170.73M, providing a cushion for debt servicing and shareholder returns.